• 1-(844)-30-STOCK

Need updates On Your Mobile Text STOCKS to 67076

Major Bounce Potential

OncoSec Medical Inc. (NASDAQ: ONCS)


Date : September 5, 2017

ONCS May have Major Bounce Potential Right Now

New Opportunity:  OncoSec Medical Inc. (NASDAQ: ONCS)

We are back in action as the Fall Trading Season kicks off. And we are looking back to the Nasdaq – in the biopharma space.

Our newest alert is ONCS: a deep value play with a strong pipeline of assets, including an orphan drug status play and a recent huge HR steal from the top-tier segment.

The chart is very interesting as the stock tests key long-term support at the $1/share level after registering strong oversold/bounce-potential readings on the key oscillators. We are also looking at a tiny float in play.

All in all, it adds up to some huge potential right now!

Symbol:  ONCS

Company:  OncoSec Medical Inc.

Quote:  http://finance.yahoo.com/q?s=ONCS

Latest News:  http://finance.yahoo.com/q/h?s=ONCS+Headlines

Company Website:  http://www.oncosec.com

Who is ONCS

ONCS stock quote

OncoSec Medical Inc. (NASDAQ: ONCS) is a biopharmaceutical company developing its proprietary DNA-based intratumoral cancer immunotherapy technology, ImmunoPulse.

OncoSec Medical’s core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based agents that target tumor-induced immune subversion pathways. ImmunoPulse is a therapeutic approach that utilizes an electroporation delivery device in combination with DNA-encoded immune target modulators to treat cancer.

Clinical studies of ImmunoPulse have demonstrated that the therapy is well-tolerated and preliminary evidence of anti-tumor activity has been observed, including the potential to initiate an immune response without the toxicities associated with systemic treatments. OncoSec Medical’s lead program is evaluating ImmunoPulse for the treatment of metastatic melanoma. A Phase 2b study is in development to evaluate ImmunoPulse in combination with a checkpoint inhibitor, called anti-PD1 (pembrolizumab), for the treatment of metastatic melanoma and is being conducted in collaboration with several prominent academic medical centers.

The company is also focused on identifying and developing new DNA-encoded proteins that target key pathways of tumor-induced immune subversion, investigating additional tumor indications, and evaluating other combination-based immunotherapy approaches.

According to a recent research piece by Zion Market Research, the global melanoma drugs market was valued at approximately $2.04B in 2016 and is expected to generate revenue of around $4.71B by end of 2022, growing at a CAGR of around 15% between 2016 and 2022.

Recent Catalysts

There are a few major catalysts in play right now for ONCS shares. One of the most important was the company’s recent announcement that it has entered a clinical trial collaboration and supply agreement with Merck (known as MSD outside the United States and Canada) to evaluate the combination of OncoSec’s ImmuoPulse® IL-12 with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in a Phase II clinical trial, referred to as PISCES.

“This is an important regulatory milestone for OncoSec as we advance ImmunoPulse® IL-12 toward commercialization,” said Punit Dhillon, CEO and President of OncoSec. “We are diligently working to address a significant unmet medical need in melanoma patients who are progressing or have progressed after treatment with anti-PD-1.”

Finally, and most recently, ONCS just announced the appointment of Annalisa Jenkins, MBBS, FRCP, CEO of Dimension Therapeutics, Inc. (DMTX), to its Board of Directors. Dr. Jenkins brings over 25 years of global industry experience to OncoSec’s Board of Directors with a wealth of knowledge in advancing programs from scientific research through clinical development, regulatory approval and into healthcare systems globally.

According to the release, Dr. Jenkins formerly served as Executive Vice President and Head of Global Research and Development for Merck Serono, a global division of Merck KGaA focused on biopharmaceuticals – making her a huge steal for the company’s brain trust.

oncs stock
ONCS stock

According to the release, the planned clinical trial will evaluate the safety and efficacy of the combination in patients with metastatic melanoma following disease progression on previous treatment with an anti-PD-1 therapy.

Just after that, we got wind from management that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for pIL-12, otherwise known as tavokinogene telsaplasmid, for the treatment of unresectable metastatic melanoma.

According to the release, Tavokinogene telsaplasmid is the active biologic agent in OncoSec’s lead product candidate, ImmunoPulse® IL-12. The Orphan Drug status will provide OncoSec with eligibility for certain development incentives, including tax credits for clinical testing, exemption from a prescription drug user fee, and seven years of market exclusivity.

Technical Analysis

The chart is what we might call “special” right now: we are looking at a test of huge long-term support on a very tight float of just 20M shares with a recent pivot/trough RSI reading down around 35 (heavily oversold) that came as part of a double-bottom test and possible trend inflection.

That’s a very rare combination – small float, long-term support, short-term support, oversold oscillator readings – that can precipitate a potentially massive bounce if the stars line up from here. Just a meager move to test the prior key pivot high would represent triple-digit percentage gain potential.

In other words, from a technical stand point, the odds are stacked in its favor right now especially well, which is exactly what we look for.

ONCS stock Chart

About ONCS

ONCS (OncoSec Medical Inc.) a company that Incorporated is a biopharmaceutical company developing its proprietary DNA-based intratumoral cancer immunotherapy technology, ImmunoPulse.

ONCS‘s core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based agents that target tumor-induced immune subversion pathways. ImmunoPulse is a therapeutic approach that utilizes an electroporation delivery device in combination with DNA-encoded immune target modulators to treat cancer. Clinical studies of ImmunoPulse have demonstrated that the therapy is well-tolerated and preliminary evidence of anti-tumor activity has been observed, including the potential to initiate an immune response without the toxicities associated with systemic treatments.

ONCS‘s lead program is evaluating ImmunoPulse for the treatment of metastatic melanoma. A Phase 2b study is in development to evaluate ImmunoPulse in combination with a checkpoint inhibitor, called anti-PD1 (pembrolizumab), for the treatment of metastatic melanoma and is being conducted in collaboration with several prominent academic medical centers.

ONCS is also focused on identifying and developing new DNA-encoded proteins that target key pathways of tumor-induced immune subversion, investigating additional tumor indications, and evaluating other combination-based immunotherapy approaches.

ONCS profile
oncs stock

Key Highlights:

    • ONCS trades on a tiny float of just 20M shares, suggesting that this stock can fly on any kind of a buzz in interest.
    • ONCS just added a critical ingredient to the board in the former SVP of Merck R&D
    • ONCS is coming off an RSI trough under 40, pointing to a massively oversold stock now heading back the other way.
    • ONCS just recorded a MACD Bullish reversal, suggesting a technical change in trend.
    • ONCS has attained Orphan Drug status with its lead pipeline asset, granting it eligibility for tax credits, exemption from a prescription drug user fee, and seven years of market exclusivity, which is HUGE.
    • ONCS is aiming its pipeline generally square at the $4.71B global melanoma drugs market (by 2022).

Conclusion:

Conclusion

ONCS has a slew of factors working in its favor right now as the chart starts to right itself at key support.

The company’s pipeline contains some very promising assets and it has the right partner in Merck to help mobilize that value. In addition, there’s no substitute for a strong team. People are always the most important part, which is why we really like to see the former SVP of R&D at a major Merck division now in a position to pass that knowledge along to help take this company to the next level.

With a small trading float and a possible inflection underway on the chart, that all adds up to a highly combustible picture right now!

Disclaimer :

We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. MyBestStockPicks engaged in the business of marketing and advertising companies. All content on our website is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. Neither the owner of Our Newsletter nor any of its members, officers, directors, contractors or employees are licensed broker-dealers, account representatives, market makers, investment bankers, investment advisors, analyst or underwriters. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here.  Mybeststockpicks owns no shares of any of the companies mentioned here within, nor intends to buy any in the future. Mybeststockpicks  has been compensated total of two thousand dollars by ALG Financial  to perform 1 week  investors awareness advertisement on ONCS starting 05/09/2017 Read Full Disclaimer 

Total Views: 1264 ,